Guidance on Platelet Transfusion for Patients With Hypoproliferative Thrombocytopenia

Transfusion Medicine Reviews

Volumn 29, Issue 1, 2015, Pages 3-13

  Nahirniak, Susan ^a   Slichter, Sherrill J ^b   Tanael, Susano ^c   Rebulla, Paolo ^d   Pavenski, Katerina ^e   Vassallo, Ralph ^f   Fung, Mark ^g   Duquesnoy, Rene ^h   Saw, Chee Loong ⁱ   Stanworth, Simon ^j   Tinmouth, Alan ^k   Hume, Heather ^l   Ponnampalam, Arjuna ^m   Moltzan, Catherine ^m   Berry, Brian ⁿ   Shehata, Nadine ^o   Allard, Shubha ^p   Anderson, David ^q   Bianco, Celso ^r   Callum, Jeannie ^s   Compernolle, Veerle ^t   Fergusson, Dean ^u   Eder, Anne ^f   Greinacher, Andreas ^v   Murphy, Michael ^w   Pink, Joanne ^x   Szczepiorkowski, Zbigniew M ^y   Whitman, Lucinda ^z   Wood, Erica ^aa   more..

^a ALBERTA HEALTH SERVICES   (Canada)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CANADIAN BLOOD SERVICES   (Canada)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f AMERICAN RED CROSS BLOOD SERVICES   (United States)

^g UNIVERSITY OF VERMONT   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j NHS BLOOD AND TRANSPLANT   (United Kingdom)

^k OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^l UNIVERSITY OF MONTREAL   (Canada)

^m UNIVERSITY OF MANITOBA   (Canada)

ⁿ UNIVERSITY OF VICTORIA   (Canada)

^o MOUNT SINAI HOSPITAL   (Canada)

^p BARTS HEALTH NHS TRUST   (United Kingdom)

^q DALHOUSIE UNIVERSITY   (Canada)

^r America's Blood Centres   (United States)

^s UNIVERSITY OF TORONTO   (Canada)

^t Rode Kruis Vlaanderen   (Belgium)

^u UNIVERSITY OF OTTAWA   (Canada)

^v UNIVERSITY OF GREIFSWALD   (Germany)

^w UNIVERSITY OF OXFORD   (United Kingdom)

^x Australian Red Cross   (Australia)

^y DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^z MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^aa MONASH UNIVERSITY   (Australia)

more..

Author keywords

Hypoproliferative thrombocytopenia; Platelet products; Platelet transfusion

Indexed keywords

IMMUNOGLOBULIN;

ALLOIMMUNIZATION; APHERESIS; AUTOTRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HLA MATCHING; HOSPITAL PATIENT; HUMAN; HYPOPROLIFERATIVE THROMBOCYTOPENIA; OUTPATIENT; REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; PRACTICE GUIDELINE; STANDARDS; TRANSFUSION MEDICINE;

HUMANS; PRACTICE GUIDELINES AS TOPIC; TRANSFUSION MEDICINE;

EID: 84921842528     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2014.11.004     Document Type: Review

References (97)

1. British Committee for Standards in Hematology Guidelines for the Use of Platelet Transfusion. Br J Haematol 2003, 122:10-23.
2. Samama C.M., Djoudi R., Lecompte T., et al. Perioperative platelet transfusion of the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) 2003. Can J Anaesth 2005, 52:30-37.
3. Bosly A., Muylle L., Noens L., et al. Guidelines for the transfusion of platelets. Acta Clin Belg 2007, 62:36-37.
4. German Medical Society Cross-sectional guidelines for therapy with blood components and plasma derivatives; platelet concentrates. Transfus Med Hemother 2009, 36:372-382.
5. Liumbruno G., Bennardello F., Lattanzio A., et al. Recommendations for the transfusion of plasma and platelets. Recommendations for the transfusion of plasma and platelets. Blood Transfus 2009, 7:132-150.
6. Tosetto A., Balduini C.L., Cattaneo M., et al. Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Hemostasis and Thrombosis (SISET). Thromb Res 2009, 124:e12-e18.
7. C17 Guidelines Committee Guideline for platelet transfusion thresholds for Pediatric Hematology/Oncology patients 2011 [Accessed October 2013]. http://www.c17.ca.
8. Dutch Blood Transfusion Guideline 2011 [Accessed October 2013]. http://www.sanquin.nl/en/products-services/blood-products/transfusion-guideline.
9. New York State Council on Human Blood and Transfusion Services Guidelines for the administration of platelets 2012, [Available at: http://www.wadsworth.org/labcert/blood_tissue/pdf/pltadmin.pdf. Accessed October 2013]. 3rd ed.
10. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001, 20:21-35.
11. Higgins J.P., Altman D.G., Gøtzsche P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. BMJ 2011, 343:d5928.
12. Fowkes F.G., Fulton P.M. Critical appraisal of published research: introductory guidelines. BMJ 1991, 302:1136-1140.
13. Bossuyt P.M., Reitsma J.B., Bruns D.E., et al. Standards for Reporting of Diagnostic Accuracy. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 2003, 326:41-44.
14. Shea B.J., Hamel C., Wells G.A., et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol 2009, 62:1013-1020.
15. Cochrane IMS [Accessed June 2011]. http://ims.cochrane.org/revman/gradepro.
16. Guyatt G., Oxman A.D., Akl E.A., et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011, 64:383-394.
17. Schünemann H.J., Best D., Vist G., et al. Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations. CMAJ 2003, 169:677-680.
18. Atkins D., Best D., Briss P.A., et al. Grading quality of evidence and strength of recommendations. GRADE Working Group. BMJ 2004, 328:1490-1494.
19. World Health Organization Handbook for guideline development 2008 [Accessed November 2012]. http://www.searo.who.int/LinkFiles/RPC_Handbook_Guideline_Development.pdf.
20. Murphy M.K., Black N.A., Lamping D.L., et al. Consensus development methods and their use in clinical guideline development. Health Technol Assess 1998, 2:1-88.
21. Estcourt L., Stanworth S.J., Doree C., et al. Prophylactic platelet transfusion for prevention of bleeding in patients with hematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev 2012, 5:CD004269.
22. Shehata N., Tinmouth A., Naglie G., et al. ABO-identical versus non-identical platelet transfusion: a systematic review. Transfusion 2009, 49:2442-2453.
23. Heddle N.M., Arnold D.M., Boye D., et al. Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion 2008, 48:1447-1458.
24. Pavenski K., Rebulla P., Duquesnoy R., et al. Efficacy of HLA-matched platelet transfusions for patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013, 53:2230-2242.
25. Vassallo R.R., Fung M., Rebulla P., et al. Utility of crossmatched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review. Transfusion 2013, 10.1111/trf.12395.
26. Gaydos L., Freireich E., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962, 266:905-909.
27. Friedmann A.M., Sengul H., Lehmann H., et al. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A re-evaluation of prophylactic platelet transfusions. Transfus Med Rev 2002, 16:34-45.
28. Han T., Stutzman L., Cohen E., et al. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study. Cancer 1966, 19:1937-1942.
29. Wandt H., Schaefer-Eckart K., Wendelin K., et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomized study. Study Alliance Leukemia. Lancet 2012, 380:1309-1316.
30. Stanworth S.J., Estcourt L.J., Powter G., et al. A no prophylaxis platelet transfusion strategy for hematologic cancers. TOPPS Investigators. N Engl J Med 2013, 368:1771-1780.
31. Estcourt L.J., Heddle N., Kaufman R., et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Biomedical Excellence for Safer Transfusion Collaborative. Transfusion 2013, 53:1531-1543.
32. Heckman K.D., Weiner G.J., Davis C.S., et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol 1997, 15:1143-1149.
33. Rebulla P., Finazzi G., Marangoni F., et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukaemia. N Engl J Med 1997, 337:1870-1875.
34. 9/L in allogeneic hematopoietic progenitor cell transplant recipients. Transfusion 2005, 45:1064-1072.
35. Slichter S.J., Harker L.A. Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978, 7:523-539.
36. Sagmeister M., Oec L., Gmür J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood 1999, 93:3124-3126.
37. Tinmouth A.T., Freedman J. Prophylactic platelet transfusions: which dose is the best dose? A review of the literature. Transfus Med Rev 2003, 17:181-193.
38. Slichter S.J., Kaufman R.M., Assmann S.F., et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362:600-613.
39. Tinmouth A., Tannock I.F., Crump M., et al. Low dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004, 44:1711-1719.
40. Heddle N.M., Cook R.J., Tinmouth A., et al. A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. SToP Study Investigators of the BEST Collaborative. Blood 2009, 113:1564-1573.
41. Sensebé L., Giraudeau B., Bardiaux L., et al. The efficiency of transfusing high doses of platelets in hematologic patients with thrombocytopenia: results of a prospective, randomized, open, blinded end point (PROBE) study. Blood 2005, 105:862-864.
42. Josephson C.D., Granger S., Assmann S.F., et al. Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood 2012, 120:748-760.
43. Riley W., Smalley B., Pulkrabek S., et al. Using lean techniques to define the platelet (platelet) transfusion process and cost-effectiveness to evaluate platelet dose transfusion strategies. Transfusion 2012, 52:1957-1967.
44. Curtis B.R., Edwards J.T., Hessner M.J., et al. Blood group A and B antigens are strongly expressed on platelets of some individuals. Blood 2000, 96:1574-1581.
45. Cooling L.L., Kelly K., Barton J., et al. Determinants of ABH expression on human blood platelets. Blood 2005, 105:3356-3364.
46. Julmy F., Ammann R.A., Taleghani B.M., et al. Transfusion efficacy of ABO major-mismatched platelets (platelets) in children is inferior to that of ABO-identical platelets. Transfusion 2009, 49:21-33.
47. Cooling L. ABO and platelet transfusion therapy. Immunohematology 2007, 23:20-33.
48. Fung M.K., Downes K.A., Shulman I.A. Transfusion of platelets containing AB incompatible plasma. Arch Pathol Lab Med 2007, 131:909-916.
49. Marktel S., Napolitano S., Zino E., et al. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. Pediatr Transplant 2010, 14:393-401.
50. Triulzi D.J., Assmann S.F., Strauss R.G., et al. The impact of platelet transfusion characteristics on post-transfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia. Blood 2012, 119:5553-5562.
51. Heal J.M., Kenmotsu N., Rowe J.M., et al. A possible survival advantage in adults with acute leukemia receiving ABO-identical platelet transfusions. Am J Hematol 1994, 45:189-190.
52. Heal J.M., Rowe J.M., McMican A., et al. The role of ABO matching in platelet transfusion. Eur J Haematol 1993, 50:110-117.
53. Carr R., Hutton J.L., Jenkins J.A., et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990, 75:408-413.
54. Dunstan R.A., Simpson M.B., Rosse W.F. Erythrocyte antigens on human platelets. Absence of Rh, Duffy, Kell, Kidd, and Lutheran antigens. Transfusion 1984, 24:243-246.
55. Gunson H.H., Stratton F., Cooper D.G., et al. Primary immunization of Rh-negative volunteers. BMJ 1970, 1:593-595.
56. Mollison P.L., Frame M., Ross M.E. Differences between Rh(D) negative subjects in response to Rh(D) antigen. Br J Haematol 1970, 19:257-266.
57. Jakobowicz R., Williams L., Silberman F. Immunization of Rh-negative volunteers by repeated injections of very small amounts of Rh-positive blood. Vox Sang 1972, 23:376-381.
58. Fournel J.J., Zingsem J., Riggert J., et al. A multicenter evaluation of the routine use of a new white cell-reduction apheresis system for collection of platelets. Transfusion 1997, 37:487-492.
59. Menitove J.E. Immunoprophylaxis for D- patients receiving platelet transfusions from D- donors?. Transfusion 2002, 42:136-138.
60. Cid J. Platelet transfusions from D+ blood donors to D- patients with hematologic diseases: an update. Transfusion 2003, 43:1759-1760.
61. Bartley A.N., Carpenter J.B., Berg M.P. D+ platelet transfusions in D- patients: cause for concern?. Immunohematology 2009, 25:5-8.
62. Molnar R., Johnson R., Sweat L.T., et al. Absence of D alloimmunization in D- pediatric oncology patients receiving D-incompatible single-donor platelets. Transfusion 2002, 42:177-182.
63. Atoyebi W., Mundy N., Croxton T., et al. Is it necessary to administer anti-D to prevent RhD immunization after the transfusion of RhD-positive platelet concentrates?. Br J Haematol 2000, 111:980-983.
64. McLeod B.C., Piehl M.R., Sassetti R.J. Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sang 1990, 59:185-189.
65. Lichtiger B., Surgeon J., Rhorer S. Rh-incompatible platelet transfusion therapy in cancer patients. A study of 30 cases. Vox Sang 1983, 45:139-143.
66. Goldfinger D., McGinniss M.H. Rh-incompatible platelet transfusions-risks and consequences of sensitizing immunosuppressed patients. N Engl J Med 1971, 284:942-944.
67. Cid J., Lozano M., Ziman A., et al. Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) study. Br J Haematol 2014, [Epub 4]. 10.1111/bjh.13158.
68. Woodruff R.K., Grigg A.P., Firkin F.C., et al. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986, 328:217-218.
69. Dalakas M.C. High dose intravenous immunoglobulin and serum viscosity: risk of precipitating thrombo-embolic events. Neurology 1994, 44:223-226.
70. MacKenzie I.Z., Bichler J., Mason G.C., et al. Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin. Eur J Obstet Gynecol Reprod Biol 2004, 117:154-161.
71. Cardo L.J., Strack M., Williams J. Anti-D for the treatment of splenectomised patients with immune thrombocytopenic purpura. Blood 1991, 78:2786-2787.
72. Claas F.H., Smeenk R.J., Schmidt R., et al. Alloimmunization against MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. Exp Hematol 1981, 9:84-89.
73. Doughty H.A., Murphy M.F., Metcalfe P., et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994, 66:200-205.
74. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997, 337:1861-1869. [No authors listed].
75. Seftel M.D., Growe G.H., Petraszko T., et al. Universal pre-storage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood 2004, 103:333-339.
76. Toor A.A., Choo S.Y., Little J.A. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant 2000, 26:315-320.
77. Kerkhoffs J.L., Eikenboom J.C., van de Watering L.M., et al. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008, 48:1959-1965.
78. Meehan K.R., Matias C.O., Rathore S.S., et al. Platelet transfusions: utilization and costs in a tertiary hospital. Am J Hematol 2000, 64:251-256.
79. Yankee R.A., Grumet F.C., Rogentine G.N. Platelet transfusion therapy-the selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969, 281:1208-1212.
80. Tosato G., Applebaum F.R., Deisseroth A.B. HLA-matched platelet transfusion therapy of severe aplastic anemia. Blood 1978, 52:846-854.
81. Duquesnoy R.J., Filip D.J., Aster R.H. Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood 1977, 50:407-412.
82. Rodey G.E., Neylan J.F., Whelchel J.D., et al. Epitope specificity of HLA class I alloantibodies: I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994, 39:272-280.
83. Vassallo R.R. New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007, 14:655-663.
84. Rebulla P., Morelati F., Revelli N., et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on crossmatching locally available platelet products. Br J Haematol 2004, 125:83-89.
85. Wiita A.P., Nambiar A. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes. Transfusion 2012, 52:2146-2154.
86. Skogen B., Christiansen D., Husebekk A. Flow cytometric analysis in platelet crossmatching using a platelet suspension immunofluorescence test. Transfusion 1995, 35:832-836.
87. Levin M.D., van der Holt B., de Veld J.C., et al. The value of crossmatch tests and panel tests as a screening tool to predict the outcome of platelet transfusion in a non-selected hematological population of patients. Vox Sang 2004, 87:291-298.
88. Daly P.A., Schiffer C.A., Aisner J., et al. Platelet transfusion therapy. One-hour post-transfusion increments are valuable in predicting the need for HLA-matched preparations. JAMA 1980, 243:435-438.
89. Dumont L.J., Szczepiorkowski Z.M. Pooled platelet concentrates or apheresis platelets?. N Engl J Med 2013, 368:1848-1849.
90. Thiele T., Heddle N., Greinacher A. Donor exposures in recipients of pooled platelet concentrates. N Engl J Med 2013, 368:487-489.
91. Tormey C.A., Sweeney J.D., Champion M.H., et al. Analysis of transfusion reactions associated with pre-storage pooled platelet components. Transfusion 2009, 49:1242-1247.
92. Wang R.R., Triulzi D.J., Qu L. Effects of pre-storage vs post-storage leukoreduction on the rate of febrile non-molytic transfusion reactions to platelets. Am J Clin Pathol 2012, 138:255-259.
93. Heddle N.M., Blajchman M.A., Meyer R.M., et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and pre-storage WBC-reduced platelets. Transfusion 2002, 42:556-566.
94. Anderson N.A., Gray S., Copplestone J.A., et al. A prospective randomized study of three types of platelet concentrates in patients with hematological malignancy: corrected platelet count increments and frequency of non-hemolytic febrile transfusion reactions. Transfus Med 1997, 7:33-39.
95. Klüter H., Dörges L., Maass E., et al. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats. Ann Hematol 1996, 73:85-89.
96. Gmür J., von Felten A., Osterwalder B., et al. Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemia. Blood 1983, 62:473-479.
97. Estcourt L.J., Pinchon D., Symington E., et al. Does bleeding affect patient-reported outcome measures in patients with myelodysplasia or hematologic malignancies: a systematic review. Transfusion 2014, 54:1166-1179.